Holiday thank-you coupon: enjoy 10% off all products

IAV M2 Specific Neutra™ Antibody Products

Product list

Are you struggling with challenges in developing broad-spectrum anti-influenza therapies or confronting issues with viral resistance and antigenic drift? Creative Biolabs' IAV M2 Specific Neutra™ Antibody Products leverage advanced antibody engineering and structural virology insights to help you develop potent, cross-reactive neutralizing agents that target a highly conserved viral epitope.

Introduction to Influenza A Virus M2 Protein

The Influenza A Virus M2 (IAV M2) protein represents a critical, multifunctional component essential for viral infectivity and replication. As a type III transmembrane proton channel, it is incorporated in low copy numbers into the virion envelope and is abundantly expressed on the surface of infected cells. IAV M2 is a 97-amino acid protein encoded by segment 7 of the viral RNA genome. It is remarkably conserved across various human and avian influenza A strains, making it a prime target for universal vaccine and therapeutic development, unlike the highly variable hemagglutinin (HA) and neuraminidase (NA) proteins.

  • Structural Insights

The functional unit is a homotetramer forming a pH-gated proton channel. Each monomer consists of a 24-residue N-terminal ectodomain (M2e), a single transmembrane helix, and a cytoplasmic C-terminal tail. The M2e region is exceptionally conserved and exposed, serving as the primary target for neutralizing antibodies. Structural studies reveal that the channel opens under acidic conditions (e.g., in the endosome), facilitating viral uncoating by allowing proton influx into the virion.

Three-dimensional structure of the influenza A M2 (AM2) ion channel. (OA Literature) Fig.1 Three-dimensional representation of the influenza A M2 (AM2) ion channel structure.1

  • Resistance and Signaling Pathways

While adamantane drugs target the M2 transmembrane domain, widespread resistance has rendered them clinically obsolete due to point mutations. This underscores the need for alternative strategies targeting non-overlapping epitopes. M2 activity is also implicated in modulating autophagy pathways in host cells and can influence inflammasome activation, linking its function to viral pathogenesis and host immune response.

Schematic diagram showing the role of the M2 protein in the IAV life cycle. (OA Literature) Fig.2 Schematic depiction illustrating the function of the M2 protein within the influenza A virus (IAV) life cycle.2

  • Clinical Impact

Influenza A virus causes seasonal epidemics and occasional pandemics, leading to significant morbidity and mortality worldwide. Complications include primary viral pneumonia, secondary bacterial pneumonia, and exacerbation of underlying cardiopulmonary diseases.

  • Antibodies Against IAV M2

Antibodies targeting the conserved M2e ectodomain offer a promising strategy to overcome the limitations of strain-specific HA/NA-targeting approaches. These antibodies primarily mediate their protective effect via Fc receptor-dependent mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), to clear infected cells, as M2 is not a major target for classical virus-neutralization in vitro.

Applications of Anti-IAV M2 Neutralizing Antibodies

  • Therapeutic Intervention for Severe Influenza

Anti-IAV M2 antibodies provide a crucial therapeutic avenue, especially against drug-resistant strains. In preclinical models, passive administration of M2e-specific monoclonal antibodies significantly reduces viral lung titers and improves survival rates, even when treatment is initiated post-infection. This approach complements antiviral drugs by leveraging the immune system to eliminate infected cells, offering a potent strategy for treating hospitalized patients with severe influenza.

  • Universal Influenza Vaccine Development

Incorporating the M2e antigen into vaccine formulations is a leading strategy for developing a "universal" influenza vaccine. Anti-M2e antibodies elicited by such vaccines provide broad protection against diverse influenza A subtypes. Our high-affinity anti-M2e antibodies are indispensable tools for evaluating immunogenicity, mapping protective epitopes, and assessing the quality of M2e-directed immune responses in vaccine development pipelines.

  • Diagnostic and Surveillance Applications

Anti-IAV M2 antibodies enable the specific detection of influenza A infection across different strains in various immunoassays. They are valuable for serosurveillance studies to understand population exposure, for developing rapid point-of-care tests that differentiate influenza A from B, and for pathological staining to identify infected cells in tissue samples, aiding in both clinical diagnostics and research.

Our Anti-IAV M2 Specific Neutra™ Antibody Products

Creative Biolabs provides rigorously validated antibodies aimed at enhancing your influenza research and therapeutic initiatives:

  • Exceptional Specificity and Affinity: Precisely target the conserved M2e epitope, ensuring minimal cross-reactivity and dependable data.
  • Diverse Validation Applications: Pre-validated for essential techniques such as ELISA, Immunofluorescence/Immunohistochemistry, and Western Blot.
  • Functional Grade Options: Offered in formats suitable for both in vitro and in vivo functional studies, including ADCC/ADCP assays and passive protection challenge models.
  • Reliable Performance: Produced under strict quality control measures to guarantee consistency across batches, supporting your critical long-term research objectives.

Creative Biolabs is your trusted partner in virology and immunology research. We combine deep scientific knowledge of targets like IAV M2 with cutting-edge production platforms to provide researchers with reliable, high-performance tools. Our antibodies are engineered to deliver the specificity, affinity, and consistency required to translate discoveries into potential therapies. Contact our scientists today to discuss how our IAV M2 Specific Neutra™ Antibody Products can be tailored to your specific project needs.

References

  1. Mtambo, Sphamadla E., et al. "Influenza viruses: harnessing the crucial role of the M2 ion-channel and neuraminidase toward inhibitor design." Molecules 26.4 (2021): 880. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/molecules26040880
  2. Manzoor, Rashid, Manabu Igarashi, and Ayato Takada. "Influenza A virus M2 protein: roles from ingress to egress." International journal of molecular sciences 18.12 (2017): 2649. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/ijms18122649
Show More Close

Inquiry

Anti-IAV M2 Neutralizing Antibody (V3S-0522-YC3647) (CAT#: V3S-0522-YC3647)

Target: IAV M2

Host Species: Human

Target Species: Influenza A virus (IAV),

Application: ELISA,Neut,

Inquiry

Recombinant Mouse Anti-IAV M2 Antibody (V3S-0522-YC4766) (CAT#: V3S-0522-YC4766)

Target: IAV M2

Host Species: Mouse

Target Species: Influenza A virus (IAV),

Application: ELISA,

Inquiry

Recombinant Anti-IAV M2 Antibody (V3S-1022-YC1729) (CAT#: V3S-1022-YC1729)

Target: IAV M2

Host Species: Human

Target Species: Influenzavirus A (A/PR/8134 and A/HK/8/68),

Application: ELISA,

For research use only, not directly for clinical use.


banner banner
© 2026 Creative Biolabs. All Rights Reserved.
antibody
ISO 9001 Certified - Creative Biolabs Quality Management System.
Online Inquiry